Biogen Inc. (NASDAQ:BIIB) is one of the most undervalued US stocks according to analysts. On June 25, Biogen announced positive topline results from an interim analysis of its Phase 1 study for ...

Biogen’s 4 nominations in the Pharma category for its Friedreich’s ataxia work included 3 in the “direct-to-patient ads for products or services” category and one in the “disease ...

Biogen is an intriguing stock that occupies one of the leading positions in the central nervous system therapeutic market. Read more on BIIB stock here.

UCB and Biogen's lupus candidate showed strong Phase 3 results, including fatigue improvement and higher remission versus standard care.

A start-up that launched only 8 months ago has attracted the attention of Biogen, a major developer of neurological drugs. City Therapeutics will develop its namesake cityRNAs—short for cleavage ...

Biogen teams up with City Therapeutics to advance RNAi therapies targeting serious diseases. Read more here.

Biogen and City Therapeutics are collaborating to develop select RNAi therapies in a $46 million partnership. City Therapeutics, a private biopharmaceutical company, will offer its RNAi ...

Cambridge-based biotechnology company Biogen Inc. announced Monday that it will move its global headquarters to a new building in Kendall Square in 2028, consolidating its various branches and ...

Biogen Inc. plans to move its headquarters into a 16-story Kendall Square tower to be developed by MIT and BioMed Realty ...

Biogen inked a 15-year lease for a building at Cambridge’s Kendall Common that the company plans to christen as its new global headquarters in 2028.

Biogen’s move comes amid a period of broad turbulence in the biotechnology industry, one that has slowed the once-voracious appetite for life-science real estate in Cambridge.

Biogen on Wednesday posted fourth-quarter revenue and profit that topped expectations as its cost cuts showed progress and new products, including its breakthrough Alzheimer's treatment Leqembi ...